Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scancell HoldingsSCNLF -16.44%16 3-1 Month Momentum % is 94.49% as of Jul. 26, 2026. GuruFocus rates SCNLF with a GF Score™ of 16/100. The stock has 1 warning sign investors should review. Among 1,395 Biotechnology companies, Scancell Holdings ranks better than 96.49% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-26), Scancell Holdings's 3-1 Month Momentum % is 94.49%.
The industry rank for Scancell Holdings's 3-1 Month Momentum % or its related term are showing as below:
SCNLF's 3-1 Month Momentum % is ranked better than 96.49% of 1395
companies
in the Biotechnology industry
Industry Median: -10.71
vs SCNLF: 94.49
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Scancell Holdings 3-1 Month Momentum % Related Terms
SCNLF vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Scancell Holdings's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings (SCNLF) has a 3-1 Month Momentum % of 94.49% as of Jul. 26, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #49 out of 1395 companies in the Biotechnology industry, placing it in the top 3.5%.
Is Scancell Holdings' 3-1 Month Momentum % too high?
Scancell Holdings' current 3-1 Month Momentum % is 94.49%. Based on the distribution chart, Scancell Holdings ranks #49 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Scancell Holdings has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #49 out of 1395 companies for 3-1 Month Momentum %. This places Scancell Holdings in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current 3-1 Month Momentum % is 94.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current 3-1 Month Momentum % of 94.49%. The current 3-1 Month Momentum % is 94.49%. Scancell Holdings' overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current 3-1 Month Momentum % is 94.49% as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
16GF Score
Get the complete analysis for SCNLF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNLF has been successfully added to your 
